Cargando…
Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data
BACKGROUND: SARS-CoV-2 testing capacity is important to monitor epidemic dynamics and as a mitigation strategy. Given difficulties of large-scale quantitative reverse transcription polymerase chain reaction (qRT-PCR) implementation, rapid antigen tests (Rapid Ag-T) have been proposed as alternatives...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407542/ https://www.ncbi.nlm.nih.gov/pubmed/34464393 http://dx.doi.org/10.1371/journal.pone.0256447 |
_version_ | 1783746641661001728 |
---|---|
author | Bello-Chavolla, Omar Yaxmehen Antonio-Villa, Neftali Eduardo Fernández-Chirino, Luisa Guerra, Enrique C. Fermín-Martínez, Carlos A. Márquez-Salinas, Alejandro Vargas-Vázquez, Arsenio Bahena-López, Jessica Paola |
author_facet | Bello-Chavolla, Omar Yaxmehen Antonio-Villa, Neftali Eduardo Fernández-Chirino, Luisa Guerra, Enrique C. Fermín-Martínez, Carlos A. Márquez-Salinas, Alejandro Vargas-Vázquez, Arsenio Bahena-López, Jessica Paola |
author_sort | Bello-Chavolla, Omar Yaxmehen |
collection | PubMed |
description | BACKGROUND: SARS-CoV-2 testing capacity is important to monitor epidemic dynamics and as a mitigation strategy. Given difficulties of large-scale quantitative reverse transcription polymerase chain reaction (qRT-PCR) implementation, rapid antigen tests (Rapid Ag-T) have been proposed as alternatives in settings like Mexico. Here, we evaluated diagnostic performance of Rapid Ag-T for SARS-CoV-2 infection and its associated clinical implications compared to qRT-PCR testing in Mexico. METHODS: We analyzed data from the COVID-19 registry of the Mexican General Directorate of Epidemiology up to April 30th, 2021 (n = 6,632,938) and cases with both qRT-PCR and Rapid Ag-T (n = 216,388). We evaluated diagnostic performance using accuracy measures and assessed time-dependent changes in the Area Under the Receiver Operating Characteristic curve (AUROC). We also explored test discordances as predictors of hospitalization, intubation, severe COVID-19 and mortality. RESULTS: Rapid Ag-T is primarily used in Mexico City. Rapid Ag-T have low sensitivity 37.6% (95%CI 36.6–38.7), high specificity 95.5% (95%CI 95.1–95.8) and acceptable positive 86.1% (95%CI 85.0–86.6) and negative predictive values 67.2% (95%CI 66.2–69.2). Rapid Ag-T has optimal diagnostic performance up to days 3 after symptom onset, and its performance is modified by testing location, comorbidity, and age. qRT-PCR (-) / Rapid Ag-T (+) cases had higher risk of adverse COVID-19 outcomes (HR 1.54 95% CI 1.41–1.68) and were older, qRT-PCR (+)/ Rapid Ag-T(-) cases had slightly higher risk or adverse outcomes and ≥7 days from symptom onset (HR 1.53 95% CI 1.48–1.59). Cases detected with rapid Ag-T were younger, without comorbidities, and milder COVID-19 course. CONCLUSIONS: Rapid Ag-T could be used as an alternative to qRT-PCR for large scale SARS-CoV-2 testing in Mexico. Interpretation of Rapid Ag-T results should be done with caution to minimize the risk associated with false negative results. |
format | Online Article Text |
id | pubmed-8407542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84075422021-09-01 Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data Bello-Chavolla, Omar Yaxmehen Antonio-Villa, Neftali Eduardo Fernández-Chirino, Luisa Guerra, Enrique C. Fermín-Martínez, Carlos A. Márquez-Salinas, Alejandro Vargas-Vázquez, Arsenio Bahena-López, Jessica Paola PLoS One Research Article BACKGROUND: SARS-CoV-2 testing capacity is important to monitor epidemic dynamics and as a mitigation strategy. Given difficulties of large-scale quantitative reverse transcription polymerase chain reaction (qRT-PCR) implementation, rapid antigen tests (Rapid Ag-T) have been proposed as alternatives in settings like Mexico. Here, we evaluated diagnostic performance of Rapid Ag-T for SARS-CoV-2 infection and its associated clinical implications compared to qRT-PCR testing in Mexico. METHODS: We analyzed data from the COVID-19 registry of the Mexican General Directorate of Epidemiology up to April 30th, 2021 (n = 6,632,938) and cases with both qRT-PCR and Rapid Ag-T (n = 216,388). We evaluated diagnostic performance using accuracy measures and assessed time-dependent changes in the Area Under the Receiver Operating Characteristic curve (AUROC). We also explored test discordances as predictors of hospitalization, intubation, severe COVID-19 and mortality. RESULTS: Rapid Ag-T is primarily used in Mexico City. Rapid Ag-T have low sensitivity 37.6% (95%CI 36.6–38.7), high specificity 95.5% (95%CI 95.1–95.8) and acceptable positive 86.1% (95%CI 85.0–86.6) and negative predictive values 67.2% (95%CI 66.2–69.2). Rapid Ag-T has optimal diagnostic performance up to days 3 after symptom onset, and its performance is modified by testing location, comorbidity, and age. qRT-PCR (-) / Rapid Ag-T (+) cases had higher risk of adverse COVID-19 outcomes (HR 1.54 95% CI 1.41–1.68) and were older, qRT-PCR (+)/ Rapid Ag-T(-) cases had slightly higher risk or adverse outcomes and ≥7 days from symptom onset (HR 1.53 95% CI 1.48–1.59). Cases detected with rapid Ag-T were younger, without comorbidities, and milder COVID-19 course. CONCLUSIONS: Rapid Ag-T could be used as an alternative to qRT-PCR for large scale SARS-CoV-2 testing in Mexico. Interpretation of Rapid Ag-T results should be done with caution to minimize the risk associated with false negative results. Public Library of Science 2021-08-31 /pmc/articles/PMC8407542/ /pubmed/34464393 http://dx.doi.org/10.1371/journal.pone.0256447 Text en © 2021 Bello-Chavolla et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Bello-Chavolla, Omar Yaxmehen Antonio-Villa, Neftali Eduardo Fernández-Chirino, Luisa Guerra, Enrique C. Fermín-Martínez, Carlos A. Márquez-Salinas, Alejandro Vargas-Vázquez, Arsenio Bahena-López, Jessica Paola Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data |
title | Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data |
title_full | Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data |
title_fullStr | Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data |
title_full_unstemmed | Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data |
title_short | Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data |
title_sort | diagnostic performance and clinical implications of rapid sars-cov-2 antigen testing in mexico using real-world nationwide covid-19 registry data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407542/ https://www.ncbi.nlm.nih.gov/pubmed/34464393 http://dx.doi.org/10.1371/journal.pone.0256447 |
work_keys_str_mv | AT bellochavollaomaryaxmehen diagnosticperformanceandclinicalimplicationsofrapidsarscov2antigentestinginmexicousingrealworldnationwidecovid19registrydata AT antoniovillaneftalieduardo diagnosticperformanceandclinicalimplicationsofrapidsarscov2antigentestinginmexicousingrealworldnationwidecovid19registrydata AT fernandezchirinoluisa diagnosticperformanceandclinicalimplicationsofrapidsarscov2antigentestinginmexicousingrealworldnationwidecovid19registrydata AT guerraenriquec diagnosticperformanceandclinicalimplicationsofrapidsarscov2antigentestinginmexicousingrealworldnationwidecovid19registrydata AT ferminmartinezcarlosa diagnosticperformanceandclinicalimplicationsofrapidsarscov2antigentestinginmexicousingrealworldnationwidecovid19registrydata AT marquezsalinasalejandro diagnosticperformanceandclinicalimplicationsofrapidsarscov2antigentestinginmexicousingrealworldnationwidecovid19registrydata AT vargasvazquezarsenio diagnosticperformanceandclinicalimplicationsofrapidsarscov2antigentestinginmexicousingrealworldnationwidecovid19registrydata AT bahenalopezjessicapaola diagnosticperformanceandclinicalimplicationsofrapidsarscov2antigentestinginmexicousingrealworldnationwidecovid19registrydata |